Drugs / Viralym-B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02313844 | Mar 2018 → Jun 2019 | polyomavirus infectious disease | AlloVir | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Viralym-B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02313844 ↗ |
| Modality | Cell therapy | “Investigators want to see if they can use a kind of white blood cell called T cells to treat BKV infections that occur after a transplant.” NCT02313844 ↗ |
| Route | Intravenous | “Partially HLA-matched Viralym-B cells will be thawed and given by intravenous injection.” NCT02313844 ↗ |